Raymond J Hohl
Overview
Explore the profile of Raymond J Hohl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1541
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koubek E, Weissenrieder J, Ortiz L, Nwogu N, Pham A, Weissenkampen J, et al.
Viruses
. 2022 Sep;
14(9).
PMID: 36146655
Merkel cell carcinoma (MCC) is a rare but aggressive form of skin cancer predominantly caused by the human Merkel cell polyomavirus (MCPyV). Treatment for MCC includes excision and radiotherapy of...
2.
Manfredi B, Neighbors J, Hohl R
Pharmacology
. 2022 Jul;
107(9-10):510-523.
PMID: 35810739
Introduction: Multiple myeloma (MM) is a B plasma cell malignancy currently incurable, and novel therapeutics are needed. Evidences regarding the effect of natural compound schweinfurthins suggest that hematological cancers showed...
3.
Zhao C, Bartock M, Jia B, Shah N, Claxton D, Wirk B, et al.
J Hematol Oncol
. 2022 May;
15(1):64.
PMID: 35590334
Despite the increased usage of post-transplant cyclophosphamide (PTCy) in allogeneic hematopoietic stem cell transplantation (allo-HSCT), our knowledge of immune reconstitution post-allo-HSCT in the setting of PTCy is limited. Adequate immune...
4.
Weissenrieder J, Weissenkampen J, Reed J, Green M, Zheng C, Neighbors J, et al.
Sci Rep
. 2022 Jan;
12(1):359.
PMID: 35013404
The schweinfurthin family of natural compounds exhibit a unique and potent differential cytotoxicity against a number of cancer cell lines and may reduce tumor growth in vivo. In some cell...
5.
Weissenrieder J, Reed J, Moldovan G, Johnson M, Trebak M, Neighbors J, et al.
Pharmacol Res Perspect
. 2021 May;
9(3):e00689.
PMID: 34003586
Dopamine D -like receptor antagonists have been suggested as being potential anticancer therapeutics with specific utility for central nervous system cancers due to their ability to cross the blood-brain barrier....
6.
Zheng H, Mineishi S, Claxton D, Zhu J, Zhao C, Jia B, et al.
Am J Hematol
. 2020 Nov;
96(2):E46-E50.
PMID: 33146922
No abstract available.
7.
McDonald A, Wasserman E, Lengerich E, Raman J, Geyer N, Hohl R, et al.
Cancer Epidemiol Biomarkers Prev
. 2020 Apr;
29(7):1365-1373.
PMID: 32277006
Background: Few studies have examined prostate cancer incidence and aggressiveness in urban-rural Appalachian populations. We examined these rates in urban-rural Appalachia and non-Appalachia Pennsylvania (PA), and the association between these...
8.
Bluethmann S, Wang M, Wasserman E, Chen C, Zaorsky N, Hohl R, et al.
Cancer Med
. 2020 Mar;
9(10):3623-3633.
PMID: 32212232
Background: To assess: (a) cancer treatment in prostate cancer survivors (PCS) by age at diagnosis (ADx) and prostate cancer (PC) aggressiveness; (b) potential impact on PC mortality; and (c) these...
9.
Weissenrieder J, Reed J, Green M, Moldovan G, Koubek E, Neighbors J, et al.
Pharmacology
. 2019 Oct;
105(1-2):19-27.
PMID: 31645049
Background: Glioblastoma multiforme (GBM) is a common and lethal cancer of the central nervous system. This cancer is difficult to treat because most anticancer therapeutics do not readily penetrate into...
10.
Larson-Casey J, Vaid M, Gu L, He C, Cai G, Ding Q, et al.
J Clin Invest
. 2019 Oct;
129(11):4962-4978.
PMID: 31609245
Macrophages are important in mounting an innate immune response to injury as well as in repair of injury. Gene expression of Rho proteins is known to be increased in fibrotic...